The nuclear receptors peroxisome proliferator-activated receptor γ (PPARγ) and its hetero-dimerization partner retinoid X receptor α (RXRα) are considered as drug targets in the treatment of diseases like the metabolic syndrome and diabetes mellitus type 2. Effort has been made to develop new agonists for PPARγ to obtain ligands with more favorable properties than currently used drugs. Magnolol was previously described as dual agonist of PPARγ and RXRα. Here we show the structure-based rational design of a linked magnolol dimer within the ligand binding domain of PPARγ and its synthesis. Furthermore, we evaluated its binding properties and functionality as a PPARγ agonist in vitro with the purified PPARγ ligand binding domain (LBD) and in a cell-based nuclear receptor transactivation model in HEK293 cells. We determined the synthesized magnolol dimer to bind with much higher affinity to the purified PPARγ ligand binding domain than magnolol (K i values of 5.03 and 64.42 nM, respectively). Regarding their potency to transactivate a PPARγ-dependent luciferase gene both compounds were equally effective. This is likely due to the PPARγ specificity of the newly designed magnolol dimer and lack of RXRα-driven transactivation activity by this dimeric compound.

Department of Biochemical Sciences Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Pharmacognosy University of Vienna Vienna Austria

Institute of Applied Synthetic Chemistry TU Wien Vienna Austria

Institute of Genetics and Animal Breeding of the Polish Academy of Sciences Jastrzebiec Poland

Institute of Pharmacy Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck University of Innsbruck Innsbruck Austria

Institute of Pharmacy Pharmacognosy and Center for Molecular Biosciences Innsbruck University of Innsbruck Innsbruck Austria

Zobrazit více v PubMed

Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435. doi: 10.1146/annurev.med.53.082901.104018. PubMed DOI

Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244–251. doi: 10.1016/j.tips.2005.03.003. PubMed DOI

Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res. 2009;60:195–206. doi: 10.1016/j.phrs.2009.03.020. PubMed DOI

Janani C, Ranjitha Kumari BD. PPAR gamma gene–a review. Diabetes Metab Syndr. 2015;9:46–50. doi: 10.1016/j.dsx.2014.09.015. PubMed DOI

Michalik L, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews. 2006;58:726–741. doi: 10.1124/pr.58.4.5. PubMed DOI

Waltenberger B, et al. Drugs from nature targeting inflammation (DNTI): a successful Austrian interdisciplinary network project. Monatsh. Chem. 2016;147:479–491. doi: 10.1007/s00706-015-1653-y. PubMed DOI PMC

Atanasov AG, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances. 2015;33:1582–1614. doi: 10.1016/j.biotechadv.2015.08.001. PubMed DOI PMC

Fakhrudin N, et al. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol Pharmacol. 2010;77:559–566. doi: 10.1124/mol.109.062141. PubMed DOI PMC

Atanasov AG, et al. Honokiol: a non-adipogenic PPARgamma agonist from nature. Biochim Biophys Acta. 2013;1830:4813–4819. doi: 10.1016/j.bbagen.2013.06.021. PubMed DOI PMC

Zhang H, et al. Molecular determinants of magnolol targeting both RXRalpha and PPARgamma. PLoS One. 2011;6:e28253. doi: 10.1371/journal.pone.0028253. PubMed DOI PMC

Kotani H, Tanabe H, Mizukami H, Makishima M, Inoue M. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J Nat Prod. 2010;73:1332–1336. doi: 10.1021/np100120c. PubMed DOI

Rycek L, Puthenkalam R, Schnurch M, Ernst M, Mihovilovic MD. Metal-assisted synthesis of unsymmetrical magnolol and honokiol analogs and their biological assessment as GABAA receptor ligands. Bioorg Med Chem Lett. 2015;25:400–403. doi: 10.1016/j.bmcl.2014.10.091. PubMed DOI PMC

Goble, S. D. et al. Alkylamino, arylamino, and sulfonamido cyclopentane amide modulators of chemokine receptor activity. Application: WO patent 2004-US43777 2005067502 (2005).

Snieckus V. Directed ortho metalation. Tertiary amide and O-carbamate directors in synthetic strategies for polysubstituted aromatics. Chem. Rev. 1990;90:879–933. doi: 10.1021/cr00104a001. DOI

Denton, R. M. & Scragg, J. T. A concise synthesis of dunnianol. Synlett, 633–635, 10.1055/s-0029-1219209 (2010).

Denton RM, Scragg JT. A strategy for the synthesis of the fargenone/fargenin family of natural products: synthesis of the tricyclic core. Org. Biomol. Chem. 2012;10:5629–5635. doi: 10.1039/c2ob25489a. PubMed DOI

Denton RM, Scragg JT, Galofre AM, Gui X, Lewis W. A concise synthesis of honokiol. Tetrahedron. 2010;66:8029–8035. doi: 10.1016/j.tet.2010.08.005. DOI

Back, T. G. & Wulff, J. E. First syntheses of two quinoline alkaloids from the medicinal herb Ruta chalepensis via cyclization of an o-iodoaniline with an acetylenic sulfone. Chemical Communications (Cambridge, United Kingdom), 1710–1711, 10.1039/b205408f (2002). PubMed

Rasolofonjatovo E, et al. Regioselective hydrostannation of diarylalkynes directed by a labile ortho bromine atom: An easy access to stereodefined triarylolefins, hybrids of combretastatin A-4 and isocombretastatin A-4. Eur. J. Med. Chem. 2010;45:3617–3626. doi: 10.1016/j.ejmech.2010.05.007. PubMed DOI

Gillis, E. P., Lee, S. J., Gray, K., Burke, M. D. & Knapp, D. M. System for controlling the reactivity of boronic acids. Application: WO patent 2007-US84156 2009014550 (2009).

Johns, B. A. & Shotwell, J. B. Preparation of benzofuranylaminoalkyl boronic acid derivatives therapeutic compounds. Application: WO patent 2011-US24822 2011103063 (2011).

Linares, M. L., Agejas, F. J., Alajarin, R., Vaquero, J. J. & Alvarez-Builla, J. Synthesis of L-2-amino-8-oxodecanoic acid: an amino acid component of apicidins. Synthesis, 2069–2073, 10.1055/s-2006-942395 (2006).

Mai E, Schneider C. Scandium-bipyridine-catalyzed enantioselective aminolysis of meso-epoxides. Chemistry - A European Journal. 2007;13:2729–2741. doi: 10.1002/chem.200601307. PubMed DOI

Tzeng S-C, Liu Y-C. Peroxidase-catalyzed synthesis of neolignan and its anti-inflammatory activity. Journal of Molecular Catalysis B: Enzymatic. 2004;32:7–13. doi: 10.1016/j.molcatb.2004.09.009. DOI

Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145–71. doi: 10.1146/annurev.cellbio.16.1.145. PubMed DOI

Rangwala SM, Lazar MA. The dawn of the SPPARMs? Sci STKE. 2002;2002:pe9. PubMed

Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of chemical information and modeling. 2005;45:160–169. doi: 10.1021/ci049885e. PubMed DOI

Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology. 1973;22:3099–3108. doi: 10.1016/0006-2952(73)90196-2. PubMed DOI